TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets the Institute of Medicine (IOM) criteria for ME/CFS~* Completing the clinically indicated invasive cardiopulmonary exercise test (iCPET)~Exclusion Criteria:~* Obesity (BMI \> 30 kg/m2)~* Non-controlled asthma~* Anemia (Hb \< 10 g/dl)~* Active or treated cancer~* History of interstitial lung disease (ILD)~* Chronic obstructive pulmonary disease (COPD)~* Pulmonary hypertension (PH)~* Congestive heart failure (CHF)~* Active arrhythmias~* Valvular heart disease~* Coronary artery disease (CAD)~* Other conditions that could predict a limitation or not completion of the study.~* Pregnancy~* Submaximal testing in clinically indicated iCPET~* Pulmonary mechanical limitation to exercise in clinically indicated iCPET.~* Pulmonary arterial hypertension in clinically indicated iCPET.~* Pulmonary venous hypertension in clinically indicated iCPET.~* Exercise induced pulmonary arterial hypertension in clinically indicated iCPET.~* Exercise induced pulmonary venous hypertension in clinically indicated iCPET.~* Persistent hypotension during or after the clinically indicated iCPET.~* Refractory arrhythmia during or after the clinically indicated level 3 CPET.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Study Drug - Pyridostigmine (Type: ACTIVE_COMPARATOR): Pyridostigmine 60 mg by mouth as a one time dose
- Placebo (Type: PLACEBO_COMPARATOR): Placebo by mouth as a one time dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Mifepristone on Uterine Fibroids and Breast Tissue

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Uterine fibroids requiring treatment~* Good general health~* Willing and able to participate after giving informed consent~Exclusion Criteria:~* Need for immediate surgery~* Concomitant hormonal treatment (HRT)~* History of malignant disorder of the breast~* Any contraindication for mifepristone~Criteria for retrospective exclusion:~Subjects may be excluded from analysis if one of the following applies:~* Any violation of the study protocol~* Lack of essential data

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- I (Type: ACTIVE_COMPARATOR): Mifepristone (Mifegyne) 50 mg every other day for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of rheumatoid arthritis.~* Currently receiving an optimal dose of oral Methotrexate (MTX)(at least 15 mg/week but no more than 25 mg/week) for the treatment of rheumatoid arthritis.~* Active rheumatoid arthritis at the time of screening.~Exclusion Criteria:~* Previous or current treatment with etanercept, other tumor necrosis factor-alpha (TNF) inhibitors, or other biologic agents.~* Concurrent treatment with any disease-modifying anti-rheumatoid drugs (DMARD), other than MTX within 28 days before baseline.~* Concurrent treatment with more than 1 non-steroid anti-inflammatory drug (NSAID) at baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Ascorbic Acid Infusion in Critically Ill Patients With Transfusion Related Acute Lung Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (18 - 64 years) critically ill patients diagnosed with transfusion related acute lung injury (TRALI), at the time of enrollment or maximum 6 hours before, according to the National Heart, Lung and Blood Institute (NHLBI) Working Group definitions and or the Canadian Consensus Conference criteria (29, 30) as the following criteria;~  * No evidence of ALI prior to transfusion.~ * Onset of ALI ≤ 6 hours following cessation of transfusion.~ * Hypoxemia, defined as the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) ≤ 300 mmHg or oxygen saturation ≤ 90% on room air.~ * Radiographic evidence of bilateral infiltrates.~ * No evidence of left atrial hypertension.~Exclusion Criteria:~* Pregnancy or breastfeeding.~* Hypernatremia or known hypersensitivity to the study drug.~* Parenteral nutrition (total/partial) containing vitamin C.~* Active renal stone or history of urolithiasis.~* Acute Kidney Injury.~* Glucose 6 phosphate dehydrogenase deficiency, iron and copper storage diseases.~* Immunocompromised patients (cancer or patients on immunosuppressive drugs).~* Moribund patient not expected to survive 24 hours .~* Home mechanical ventilation (via tracheotomy or noninvasive) except for Continuous Positive Airway Pressure/ Bilevel Positive Airway Pressure (CPAP/BIPAP) used only for sleep-disordered breathing .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- ASTRALI Group (Type: EXPERIMENTAL): ASTRALI (AScorbic acid in TRALI) group (n=40)
- Control Group (Type: PLACEBO_COMPARATOR): Control group (n=40)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A history of heartburn or acid regurgitation for 3 months or longer or any history of erosive esophagitis.~* Nightime heartburn averaging at least 2 or 3 times per week and a history of sleep disturbances associated with GERD for 1 month or more.~* Nightime heartburn graded as moderate or severe on 3 of the last 7 days of the run-in period and sleep disturbances associated with GERD as documented in the run-in diary card on at least 3 of the last 7 days of the run-in period..~Exclusion Criteria:~* Any condition other than GERD that is either the primary cause of, or a significant contributor to the patients sleep disturbance.~* Shift workers who work between 12am (midnight) and 6am.~* Sleep medication, antihistamine, benzodiazepine, or anti-anxiety medication use that has not been stable for at least 3 months or is not expected to remain stable during the patients participation in the study.~* Other diseases / conditions as listed in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18 to 70 years~* NAFLD, defined by confirmed hepatic steatosis by imaging or by liver biopsy, in the absence of other causes of hepatic steatosis or significant alcohol consumption. If liver imaging or biopsy has not been performed clinically, liver ultrasound assessment will be performed as part of the screening visit.~* Early-stage liver fibrosis, defined as fibrosis less than or equal to Fibrosis Stage 3 (F3), confirmed by either (1) a recent liver biopsy or (2) a recent elastography / Fibroscan study. If no recent biopsy or elastography/Fibroscan have been performed, a Fibroscan will be performed as part of the screening visit.~Exclusion Criteria:~* Liver fibrosis stage \> 3~* Current aspirin use~* Contraindications to aspirin use~* Contraindications to magnetic resonance imaging (MRI)~* Pregnancy or desire to become pregnant~* Breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: EXPERIMENTAL): Low-dose (81mg) aspirin tablets
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rosuvastatin Affecting Aortic Valve Endothelium

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: DEFINED_POPULATION
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Asymptomatic AS~* Normal ejection fraction~* Elevated LDL \>130 mg/dl~Exclusion Criteria:~* Echocardiographic evidence of rheumatic mitral valve disease,~* Previous statin therapy,~* Congenital heart disease (bicuspid aortic valve),~* Subaortic obstruction,~* Creatinine ≥ 2,0 mg/dl (to avoid the potential confounder of an elevated serum \[CaP04\]),~* Evidence of liver disease,~* Greater than mild aortic regurgitation and previous aortic valve surgery

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with cholestatic disorders and healthy subjects~Exclusion Criteria:~* Body weight above 110 kg (catheterization problematic).~* Diabetes~* Pregnant or breast feeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ICG's effect on 11C-CSar transport (Type: EXPERIMENTAL): Examine the effect of ICG on the kinetics of the hepatic transport of 11C-CSar. If no effect is seen on the kinetics, ICG will be used during the infusion method experiments.
- Infusion method (Type: EXPERIMENTAL): Determine wether bolus or constant infusion of 11C-CSar is optimal for the PET/CT scanning. If ICG does not affect the kinetics of 11C-CSar it will be used during these experiments to calculate hepatic blood flow.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of SPMS~* Age 40-70 years~* Able to understand English and able to give informed consent~Exclusion Criteria:~* Unable to undergo MRI testing~* For ambulatory subjects only, a self-reported medical or neurological condition other than MS that is a cause of progressive or fluctuating problems that affect walking(e.g. worsening neuropathy, uncontrolled lower extremity arthritis, uncontrolled heart or lung disease)~* For ambulatory subjects only, fixed and/or stable conditions of less than 1 years duration that affect walking (e.g. joint replacement, lumbar stenosis, alcoholism, stroke, etc.)~* Pregnant or breast-feeding.~* Current major disease or disorder other than MS (such as cancer, kidney, heart or lung disease, post-traumatic stress disorder) that may interfere with study procedures~* Natalizumab, mitoxantrone, azathioprine taken in the last 12 months~* Other immunosuppressants or chemotherapies taken in the last 12 months~* Scheduled (every 3 months or more frequently) IV steroids used in the last 12 months~* IV or oral steroids taken in the past 60 days.~* Lipoic acid taken in the past 60 days.~* Subject has insulin-dependent diabetes or is not controlled on oral diabetes medications

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: lipoic acid (Type: EXPERIMENTAL): 28 subjects receive oral lipoic acid 1200mg daily
- Arm 2: placebo (Type: PLACEBO_COMPARATOR): 28 subjects receive placebo daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Scheduled for atherosclerotic vascular elective surgery with presumed fast-track,~* Cardiac ischaemic risk supported by:~  * History of myocardial infarction older than 1 month and/or~ * Documented Stable angina (asymptomatic ± medical treatment) and/or~ * History of coronary revascularisation, and/or~ * Surgical Risk Index (Lee index) ≥ 3.~ * Written informed consent~Exclusion Criteria:~* Unstable angina within the last 30 days,~* Non controlled arterial Hypertension .~* Severe Cardiac heart Failure (NYHA IV)~* Severe Chronic Obstructive Pulmonary Disease~* Patient already randomized in another ongoing clinical trial~* Patient with recent myocardial infarction (M.I) (less than one month )~* Patient already included in a clinical trial~* History of hypersensitivity to study drugs( i.e Xenon, propofol, sevoflurane, desflurane, isoflurane)~* Malignant hyperthermia~* Documented Elevated intracranial pressure~* Preeclampsia or eclampsia~* Pregnancy and lactation~* Presumed uncooperativeness or legal incapacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Xenon (Type: EXPERIMENTAL): 0.8-1.1 minimum alveolar concentration (MAC) Xenon in 30 % oxygen (Group A)
- sevoflurane (Type: ACTIVE_COMPARATOR): 0.8-1.1 Minimum Alveolar Concentration (MAC) Sevoflurane in 30 % oxygen (Group B)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants with T1DM diagnosed for at least 12 months and had been treated with insulin glargine and Humalog or Novolog®/Novo Rapid® (at least 3 times daily before each meal) in the 6 months prior to the screening visit.~* Written informed consent.~Exclusion criteria:~* At screening visit, age under legal age of adulthood.~* HbA1c \<7.0% or \>10% at screening.~* Diabetes other than T1DM.~* Status post pancreatectomy.~* Status post pancreas and/or islet cell transplantation.~* Pregnancy and lactation.~* Women of childbearing potential not protected by highly effective contraceptive method of birth control.~* Less than 1 year on continuous insulin treatment.~* Use of insulin pump in the last 6 months before screening visit.~* Use of glucose lowering treatments other than insulin including non-insulin injectable peptides in the last 6 months prior to screening visit.~* Use of insulin other than insulin glargine and Humalog or Novolog/Novo Rapid as part of a multiple injection regimen (3 to 4 injections per day) in the last 6 months before screening visit. Liprolog® is a European Union approved insulin lispro and is allowed in those countries where it is marketed.~* Hospitalization for diabetic ketoacidosis in the last 6 months before screening visit.~* Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment, or injectable drugs) during the study period.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SAR342434 (Type: EXPERIMENTAL): SAR342434 before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
- Humalog (Type: ACTIVE_COMPARATOR): Humalog before meals intake on top of QD Insulin Glargine, up to Week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients 12 years old or above with moderate to severe allergic asthma~* Body weight greater than 30kg and less than 150 kg and total serum IgE level greater than 30 to less than 700 IU/ml~* Diagnosis of allergic asthma greater than 1 year duration, according to the American Thoracic Society criteria (14) and at screening, a history consistent with clinical features of moderate to severe persistent asthma.~* Positive skin prick test (diameter of wheel is greater than 3mm) to at least one perennial allergen within the previous one year to visit 1, to which the patient will be exposed on a regular basis (most days) for the duration of the study.~* No clinically significant asthma exacerbations that required treatment with systemic corticosteroids during the four weeks immediately prior to screening visit (Visit 1) and during screening period (between Visit 1 and 2)~* Demonstrated evidence of inadequate asthma symptom control, despite treatment with ICS according to clinical features of moderate to severe persistent asthma.~Exclusion Criteria:~* Previous exposure to omalizumab~* Previous exposure to other humanized proteins or monoclonal antibodies~* Known HAHA to other monoclonal antibodies~* History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures~* Known hypersensitivity to any ingredients, including excipients of the study medication or drugs related to omalizumab (e.g. monoclonal antibodies, polyclonal gamma globulin)~* Active lung disease other than allergic asthma (e.g. cystic fibrosis, bronchiectasis)~* Elevated serum IgE levels for reasons other than allergy (e.g. parasite infections, hyperimmunoglobulin E syndrome, Wiskott-Aldrich Syndrome or allergic bronchopulmonary aspergillosis)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* chronic renal anemia;~* maintenance hemodialysis or peritoneal dialysis for \>=2 weeks before screening, and during screening period.~Exclusion Criteria:~* previous therapy with epoetin within 8 weeks prior to screening;~* overt gastrointestinal bleeding within 8 weeks before screening or during screening period;~* RBC transfusions within 8 weeks before screening or during screening period;~* active malignant disease except non-melanoma skin cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Correction Phase: CERA (Type: EXPERIMENTAL): None
- Correction Phase: Epoetin Beta (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete